Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses whether companies' promises to stop raising drug prices will benefit patients.
Transcript:
Well, I was just reading this morning that the now soon-departing CEO of Pfizer actually said that business will return to normal next year, so despite some of the price stalling that has gone on, I don’t think that’s going to change. I think they’re just waiting to have the public elections happens, see what happens, waiting for the issues to shift somewhere else and then they’ll start all over again.
If we look at the trends over the last 6 to 8 years, we’ve seen price hikes on average of 68%. There’s no reason to think that the pharmaceutical companies are going to stop hiking the prices, and this is why we believe it is imperative we start to be more strict with how we give pharmaceutical companies the power through the patent system and other exclusivities such that they’re able to do this over and over again, as our reports have shown, the longer they have these exclusivities for, they annually hike these prices up. I don’t see that being a solution.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.